Literature DB >> 30267010

The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.

Tobias W Klausen1, Henrik Gregersen2, Niels Abildgaard3, Niels Frost Andersen4, Ulf Christian Frølund5, Peter Gimsing6, Carsten Helleberg1, Annette J Vangsted7.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30267010     DOI： 10.1038/s41375-018-0272-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

1.  Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.

Authors:  Song-Yau Wang; Tanja Holzhey; Simone Heyn; Thomas Zehrfeld; Susann Fricke; Franz Albert Hoffmann; Cornelia Becker; Leanthe Braunert; Thomas Edelmann; Inessa Paulenz; Marcus Hitzschke; Franziska Flade; Andreas Schwarzer; Klaus Fenchel; Georg-Nikolaus Franke; Vladan Vucinic; Madlen Jentzsch; Sebastian Schwind; Saskia Hell; Donata Backhaus; Thoralf Lange; Dietger Niederwieser; Markus Scholz; Uwe Platzbecker; Wolfram Pönisch
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-20       Impact factor: 4.322

2.  Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.

Authors:  Yan-Ting Chen; Erik T Valent; Erik H van Beers; Rowan Kuiper; Stefania Oliva; Torsten Haferlach; Wee-Joo Chng; Martin H van Vliet; Pieter Sonneveld; Alessandra Larocca
Journal:  Int J Lab Hematol       Date:  2021-08-26       Impact factor: 3.450

3.  Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.

Authors:  H Tilman Steinmetz; Moushmi Singh; Andrea Lebioda; Sebastian Gonzalez-McQuire; Achim Rieth; Martina Schoehl; Wolfram Poenisch
Journal:  Oncol Res Treat       Date:  2020-07-21       Impact factor: 2.825

Review 4.  Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

Authors:  Evangelos Terpos; Joseph Mikhael; Roman Hajek; Ajai Chari; Sonja Zweegman; Hans C Lee; María-Victoria Mateos; Alessandra Larocca; Karthik Ramasamy; Martin Kaiser; Gordon Cook; Katja C Weisel; Caitlin L Costello; Jennifer Elliott; Antonio Palumbo; Saad Z Usmani
Journal:  Blood Cancer J       Date:  2021-02-18       Impact factor: 11.037

5.  Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives.

Authors:  Aniek Dane; Soedaba Ashraf; James Timmis; Monique Bos; Carin Uyl-de Groot; P Hugo M van der Kuy
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

6.  Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016.

Authors:  Iiro Toppila; Kai Kysenius; Tatu Miettinen; Mariann Ida Lassenius; Juha Lievonen; Pekka Anttila
Journal:  Ann Hematol       Date:  2022-09-13       Impact factor: 4.030

7.  Treatment burden in multiple myeloma according to comorbidity in real life.

Authors:  Ernesto Pérez Persona; Itziar Oiartzabal Ormategui; Laida Cuevas Palomares; Ana Santamaría López; Diego Robles de Castro; Carlos Miguel de Sánchez; Miren Gabilondo Jalón; Carlos Pisón Herrero; Ariane Unamunzaga Cilaurren; Ana Vega González de Viñaspre; Jose María Guinea de Castro
Journal:  Ann Hematol       Date:  2021-03-05       Impact factor: 3.673

8.  Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.

Authors:  Mohamad Mohty; Wolfgang Knauf; Dorothy Romanus; Shelby Corman; Katharina Verleger; Youngmin Kwon; Dasha Cherepanov; M Janelle Cambron-Mellott; Haris G Vikis; Francisco Gonzalez; Francois Gavini; Karthik Ramasamy
Journal:  Eur J Haematol       Date:  2020-06-09       Impact factor: 2.997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.